SCHEMBL30368259

SCHEMBL30368259

CC(=O)Nc1cc(NC(=O)Cc2ccccc2C(F)(F)F)ccn1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 9/20 0.66
CSF1R P07333 1/20 0.64
PDGFRB P09619 1/20 0.64
KIT P10721 1/20 0.64
PDGFRA P16234 1/20 0.64
FLT3 P36888 1/20 0.64
PIK3C3 Q8NEB9 1/20 0.52
NR3C2 P08235 1/20 0.51
JAK2 O60674 1/20 0.50
JAK1 P23458 1/20 0.50
TYK2 P29597 1/20 0.50
NR2E1 Q9Y466 1/20 0.50
KCNJ5 P48544 1/20 0.49
KCNJ3 P48549 1/20 0.49
GRK2 P25098 1/20 0.48
NTRK1 P04629 1/20 0.44
MAPKAPK2 P49137 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368264 0.89 JAK2 (0.55) ANO1CSF1RPDGFRBKITPDGFRA
SCHEMBL30368445 0.84 NTRK1 (0.51) ANO1CSF1RPDGFRBKITPDGFRA
SCHEMBL30368170 0.84 ANO1 (0.51) ANO1CSF1RPDGFRBKITPDGFRA
SCHEMBL22528884 0.83 CSF1R (0.74) ANO1CSF1RPDGFRBKITPDGFRA
SCHEMBL30368230 0.82 JAK2 (0.62) ANO1JAK2JAK1TYK2KCNJ5
SCHEMBL31240720 0.80 RIOK2 (0.57) ANO1CSF1RPDGFRBKITPDGFRA
SCHEMBL21198049 0.79 ANO1 (1.00) ANO1
SCHEMBL30368345 0.79 JAK2 (0.52) ANO1NR3C2JAK2JAK1TYK2
SCHEMBL22528746 0.79 CSF1R (1.00) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL22528781 0.79 CSF1R (0.68) ANO1CSF1RPDGFRBKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171744-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed
EP-4172146-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY Bayer Aktiengesellschaft (DE) 2023-05-03 EP disclosed